The Medicare Multi-Cancer Early Detection Screening Coverage Act will:

• Establish a coverage pathway under Medicare for certain Food and Drug Administration (FDA)-approved MCED tests, which can screen for dozens of cancer types, many of which currently lack an effective screening option; 
• Authorize the Centers for Medicare and Medicaid Services (CMS) to provide Medicare coverage for FDA-approved MCED screening tests, enabling beneficiaries to access these technologies, which currently lack a viable coverage pathway under the program;
• Maintain CMS authority to use an evidence-based process to determine coverage parameters for these new tests; and 
• State that new diagnostic technologies will supplement, not replace, existing screenings and will not impact existing coverage and cost-sharing.